Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AIN457 (secukinumab) in moderate to severe Crohn's disease
2008-008359-40Phase 2Completed
- Sponsor
- Novartis
- Start
- Mar 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Crohn's disease comparing AIN457 (secukinumab) arm with Placebo arm (2 arms). Primary endpoint: Primary efficacy endpoint: change in CDAI at week 6. Started Mar 2009; status: completed.
02
Drugs
secukinumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2008-008359-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-008359-40.